Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00985049 · ClinicalTrials.gov registry record

TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)

A clinical trial of Cardiovascular Diseases, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
350
Enrollment target
1
Study location

NCT00985049 is a study of Cardiovascular Diseases that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 350 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00985049, a study of Cardiovascular Diseases, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
350 participants
Enrollment target
1
Study location

Study Summary

Hypothesis: The investigators hypothesize that genetic variants will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemia. This will be compared to blood gene expression in blood cells and analyzed with the patients' genetic profile. This might allow us to assess the amount of inflammation that occurs when patients are on the heart-lung machine as well as examine the effects genes have on this critical time period.

Conditions Studied

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2009-03
Est. Completion 2025-12

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT00985049

The ClinicalTrials.gov registry entry for NCT00985049 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT00985049 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00985049 about?

NCT00985049 is a clinical study titled "TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)". Hypothesis: The investigators hypothesize that genetic variants will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemi...

What is the current status of trial NCT00985049?

This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2009-03. Estimated completion is 2025-12.

What conditions does trial NCT00985049 study?

This clinical trial studies the following conditions: Cardiovascular Diseases.

Who is sponsoring clinical trial NCT00985049?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00985049 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.